Paola Bigolin

Paola Bigolin

Auto-generated profile, based on publicly available information

Paola Bigolin

Angiology Unit, Azienda ULSS 2 Marca Trevigiana, Castelfranco Veneto, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Life
Verified
Journal Article
Open access
PDF file
BZBeniamino Zalunardo
Beniamino Zalunardo
CPChiara Panzavolta
Chiara Panzavolta
PBPaola Bigolin
Paola Bigolin
AVAdriana Visonà
Adriana Visonà
Cancer is a leading cause of death. Venous thromboembolism (VTE) is an often-overlooked cause of morbidity and mortality in cancer patients that can be readily prevented and treated. Actions are needed to reduce the morbidity and mortality of patients with cancer-associated thrombosis (CAT). There is a need to increase awareness of the impact of CAT on cancer patients’ morbidity and mortality, on their quality of life and to understand the importance of more effective preventions and treatments of VTE in cancer patients. Moreover, it is of great importance to systematically assess the risk of VTE in regard to patients, cancer and treatment-related factors. Unfortunately, there are unmet clinical needs in the prevention and treatment of cancer-associated VTE. In this review, we discuss an action plan to ensure an increased awareness of and education on the issues that need to be addressed in order to improve the provision of appropriate prevention, early diagnosis and effective and safe treatment of VTE to all cancer patients and, ultimately, to reduce morbidity and mortality.

1 July 2025 in Vasa
Verified
Journal Article
Closed access
GBGiacomo Buso
Giacomo Buso
JHJeanne Hersant
Jeanne Hersant
SKSanjiv Keller
Sanjiv Keller
IKIgli Kalaja
Igli Kalaja
PBPaola Bigolin
Paola Bigolin
LMLucia Mazzolai
Lucia Mazzolai
Summary: The new guidelines for the management of peripheral arterial and aortic diseases (PAAD) from the European Society of Cardiology and endorsed by the European Society of Vascular Medicine (ESVM), emphasize on a comprehensive and multidisciplinary approach focusing on prevention, diagnosis, treatment, and follow-up of patients with a wide range of PAAD, including lower extremity peripheral arterial disease (PAD). The aim of this summary, focusing on PAD and coordinated by the Young Academy of ESVM, is to provide young angiologists with the fundamental principles of these guidelines and to assist them in navigating their everyday clinical practice. PAD diagnosis relies on objective evaluation of flow/oxygen reduction at rest, with arterial ultrasound as the first imaging modality to confirm the presence of arterial lesions. The main goals of PAD management are not only to improve functioning and prevent the occurrence of adverse events at the lower limb level, but also to reduce the overall atherosclerotic burden and achieve the general well-being of patients. To this end, traditional and nontraditional cardiovascular risk factors need to be properly addressed through lifestyle changes and tailored drug therapies. For patients with exertional limb symptoms, supervised exercise training is recommended. Interventional treatment is indicated for limb salvage in patients with chronic limb threatening ischemia and may also be discussed in a multidisciplinary setting in less severe patients with persisting symptoms and reduced quality of life after a minimum period of optimal medical treatment including exercise therapy. For trainees or young specialists in Angiology/Vascular Medicine, these guidelines provide essential elements to improve patient management, encourage interdisciplinary collaboration, and ensure an integrated approach to vascular diseases.

1 November 2022 in Vasa
Verified
Journal Article
Closed access
PBPaola Bigolin
Paola Bigolin
BZBeniamino Zalunardo
Beniamino Zalunardo
LMLucia Mazzolai
Lucia Mazzolai
JBJill Belch
Jill Belch
AVAdriana Visonà
Adriana Visonà
Summary: Background: Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality globally. Methods: the integrated care pathways (ICPs) are tools through which evidence-based guidelines (GLs) on a specific disease or clinical topic can be implemented in a clinical process. Aim: This study aims to facilitate decision making for health professionals in their daily practice. Results: This model, according with the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines, supports the multifactorial evaluation of global cardiovascular (CV) risk and suggests using algorithms and revised cardiovascular risk stratification, specifically for high- and very-high-risk patients. Conclusions: Multidimensional and integrated actions are aimed at eliminating and/or minimizing the impact of cardiovascular disease, improving the quality and consistency of vascular prevention, and leading to optimal clinical decisions.

7 December 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
GBGiacomo Buso
Giacomo Buso
PSPaolo Santini
Paolo Santini
FGFrancesca Ghirardini
Francesca Ghirardini
PBPaola Bigolin
Paola Bigolin
RMromeo martini
romeo martini
ONon behalf of the SIAPAV Working Group on Venoactive Nutraceuticals
on behalf of the SIAPAV Working Group on Venoactive Nutraceuticals
Background: Chronic venous disease (CVD) is a prevalent condition associated with significant morbidity and impaired quality of life. Venoactive nutraceuticals are widely used as part of conservative management and are cited in major guidelines, yet recommendations remain heterogeneous and clinical practice varies substantially. This study aimed to establish expert consensus on the clinical use of these agents in CVD within the Italian vascular community. Methods: A three-round modified Delphi was conducted among 21 Italian vascular specialists (May–July 2025). Consensus was defined as ≥70% agreement. Statements addressed CEAP classification, symptom assessment, use and perceived effectiveness of individual agents, combination regimens, and topical formulations. Results: Consensus supported routine use of CEAP and its 2020 revision, the clinical distinction between CVD (C0–C2) and chronic venous insufficiency (CVI) (C3–C6), and systematic classification of patients as symptomatic or asymptomatic. Strong agreement endorsed the use of selected venoactive nutraceuticals across all CEAP classes and supported combination therapy as more effective than monotherapy. An oral fixed-dose combination of diosmin, ruscus, melilotus, Vitis vinifera, and horse chestnut extract, pre-selected as a test case to evaluate the plausibility of combining agents with complementary mechanisms, was considered a reasonable first-line conservative option. Topical preparations were endorsed across C1–C6, particularly for CVI and to reduce heaviness, reflecting their perceived value as safe adjuncts despite the limited availability of high-quality evidence. No consensus was reached for ruscus, horse chestnut, hydroxyethylrutosides, red vine leaf extract, anthocyanosides, or β-arbutin in monotherapy. The panel agreed on the need to update clinical guidelines to reflect emerging evidence on venoactive nutraceuticals. Conclusions: This Delphi provides structured expert consensus on the use of venoactive nutraceuticals in CVD. Combination therapy integrating multiple physiological effects is considered more effective than single agents. Further research is required to validate combination regimens and topical formulations and to determine their impact on patient-reported outcomes.

1 May 2026 in Vasa
Verified
Journal Article
Closed access
GBGiacomo Buso
Giacomo Buso
JHJeanne Hersant
Jeanne Hersant
SKSanjiv Keller
Sanjiv Keller
IKIgli Kalaja
Igli Kalaja
PBPaola Bigolin
Paola Bigolin
LMLucia Mazzolai
Lucia Mazzolai
Summary: Background: Vascular medicine/angiology plays a crucial role in managing vascular diseases, yet its recognition, training, and practice vary across Europe. To understand these disparities, the European Society for Vascular Medicine (ESVM) conducted a survey among young trainees to assess their attitudes and perception towards vascular medicine training. Methods: A cross-sectional survey was distributed among trainees and young specialists from European countries, including nations with and without vascular medicine as a recognized specialty. The survey was published on the ESVM website and shared through national vascular medicine societies. Participants provided insights into their training experiences, opinions of the specialty, and priorities for improvement. Statistical analysis compared responses based on specialty recognition. Findings: Among 210 respondents, 36.2% (n=76) were from countries without formal specialty recognition. Training was more structured in countries with a recognized specialty (p<.001). Multidisciplinary team meetings were deemed critical by 98.1% but were more common in countries with a recognized specialty (p=.003). Overall, 80.5% (n=169) expressed interest in training abroad. Core vascular domains were well-covered, while areas like lymphatic and microvascular diseases lacked sufficient training both in countries where the specialty was recognized and where it was not. Respondents from countries with a recognized specialty rated their training significantly higher (p=.001). Despite challenges, 85.2% (n=179) would choose the specialty again, and 90.4% (n=190) supported a unified European certification. Interpretation: These findings highlight the need for a harmonized training framework in Europe ensuring a shared foundational curriculum in vascular medicine while enhancing professional mobility and improving patient care across the whole spectrum of vascular diseases.

1 January 2017 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
PDF file
PBP. Bigolin
P. Bigolin
AAA. Antonucci
A. Antonucci
RMR. Marin
R. Marin
DVD. Vianello
D. Vianello
SBS. Bertocco
S. Bertocco
SZS. Zambon
S. Zambon